Jefferies keeps Ventiv at buy

Ventiv Health was maintained at its buy rating by Jefferies & Co., Inc. analyst David Windley due in part to management's expansion of the Ventiv (now inVentiv) platform to a multi-pronged service offering for biopharma clients. The company reported fourth-quarter earnings of $0.34 per share compared with Jefferies' expectations and consensus of $0.28 per share. Shares of the Somerset, N.J., pharmaceutical services company were up $1.87, or 6.42%, at $31.00 on volume of 1,723,340 shares versus the three-month running average of 317,649 shares. (Nasdaq: VTIV)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.